Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
irinotecan liposome + nab-paclitaxel + gemcitabine is a combination chemotherapy regimen being evaluated as a first-line treatment for patients with locally advanced or metastatic pancreatic cancer. The regimen combines three active agents: irinotecan liposome (a topoisomerase I inhibitor encapsulated in a long-circulating liposomal formulation), nab-paclitaxel (an albumin-bound nanoparticle formulation of the microtubule inhibitor paclitaxel), and gemcitabine (a nucleoside analog that inhibits DNA synthesis). This combination is currently being studied in a Phase I/II investigator-initiated trial at Harbin Medical University to determine its safety and efficacy compared to standard doublet or triplet therapies. The liposomal and nanoparticle delivery systems are designed to enhance intratumoral drug concentration and reduce systemic toxicity.
- Other names
- Liposomal irinotecan plus nab-paclitaxel and gemcitabineIrinotecan liposome + albumin paclitaxel + gemcitabine
02
Targets
RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposome + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + nab-paclitaxel + gemcitabine.